Anti-β(s)-ribozyme reduces β(s) mRNA levels in transgenic mice: Potential application to the gene therapy of sickle cell anemia

Raouf Alami, John G. Gilman, Y. Q. Feng, Antonietta Marmorato, Ilia Rochlin, Sandra M. Suzuka, Mary E. Fabry, Ronald L. Nagel, Eric E. Bouhassira

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Our current strategy for gene therapy of sickle cell anemia involves retroviral vectors capable of transducing 'designer' globin genes that code for novel anti-sickling globins (while resisting digestion by a ribozyme), coupled with the expression of a hammerhead ribozyme that can selectively cleave the human β(s) mRNA. In this report, we have tested in vivo an anti- β(s) hammerhead ribozyme embedded within a cDNA coding for the luciferase reporter gene driven by the human β-globin promoter and hyper-sensitive sites 3 and 4 of the locus control region. We have created mice transgenic for this luciferase-ribozyme construct and bred the ribozyme transgene into mice that were already transgenic for the human β(s) gene. We then measured expression of the β(s) transgene at the protein and RNA levels by HPLC and primer extension. The presence of the ribozyme was associated with a statistically significant reduction in the level of β(s) mRNA in spleen stress reticulocytes (from 60.5±4.1% to 52.9 ± 4.2%) and in the percentage of β(s) globin chains in very young mice (from 44.5 ± 0.6% to 40.8 ± 0.7%). These results demonstrate that it is possible to decrease the concentration of β(s) chains and mRNA with the help of a hammerhead ribozyme. While the enormous amount of globin mRNA in reticulocytes is a challenge for ribozyme technology, the exquisite dependence of the delay time for formation of Hb S nuclei on the concentration of Hb S in red blood cells suggests that even a modest reduction in Hb S concentration would have therapeutic value.

Original languageEnglish (US)
Pages (from-to)110-119
Number of pages10
JournalBlood Cells, Molecules, and Diseases
Volume25
Issue number2
DOIs
StatePublished - Apr 1999

Fingerprint

Catalytic RNA
Globins
Sickle Cell Anemia
Genetic Therapy
Transgenic Mice
Messenger RNA
Reticulocytes
Luciferases
Transgenes
Locus Control Region
Reporter Genes
Genes
Digestion
Spleen
Complementary DNA
Erythrocytes
High Pressure Liquid Chromatography
RNA
Technology
hammerhead ribozyme

Keywords

  • Beta-globin
  • Gene therapy
  • Hammerhead ribozyme
  • Mouse model
  • Sickle cell anemia

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology

Cite this

Anti-β(s)-ribozyme reduces β(s) mRNA levels in transgenic mice : Potential application to the gene therapy of sickle cell anemia. / Alami, Raouf; Gilman, John G.; Feng, Y. Q.; Marmorato, Antonietta; Rochlin, Ilia; Suzuka, Sandra M.; Fabry, Mary E.; Nagel, Ronald L.; Bouhassira, Eric E.

In: Blood Cells, Molecules, and Diseases, Vol. 25, No. 2, 04.1999, p. 110-119.

Research output: Contribution to journalArticle

Alami, Raouf ; Gilman, John G. ; Feng, Y. Q. ; Marmorato, Antonietta ; Rochlin, Ilia ; Suzuka, Sandra M. ; Fabry, Mary E. ; Nagel, Ronald L. ; Bouhassira, Eric E. / Anti-β(s)-ribozyme reduces β(s) mRNA levels in transgenic mice : Potential application to the gene therapy of sickle cell anemia. In: Blood Cells, Molecules, and Diseases. 1999 ; Vol. 25, No. 2. pp. 110-119.
@article{704e626c61674f4ba3835bdfa91b5232,
title = "Anti-β(s)-ribozyme reduces β(s) mRNA levels in transgenic mice: Potential application to the gene therapy of sickle cell anemia",
abstract = "Our current strategy for gene therapy of sickle cell anemia involves retroviral vectors capable of transducing 'designer' globin genes that code for novel anti-sickling globins (while resisting digestion by a ribozyme), coupled with the expression of a hammerhead ribozyme that can selectively cleave the human β(s) mRNA. In this report, we have tested in vivo an anti- β(s) hammerhead ribozyme embedded within a cDNA coding for the luciferase reporter gene driven by the human β-globin promoter and hyper-sensitive sites 3 and 4 of the locus control region. We have created mice transgenic for this luciferase-ribozyme construct and bred the ribozyme transgene into mice that were already transgenic for the human β(s) gene. We then measured expression of the β(s) transgene at the protein and RNA levels by HPLC and primer extension. The presence of the ribozyme was associated with a statistically significant reduction in the level of β(s) mRNA in spleen stress reticulocytes (from 60.5±4.1{\%} to 52.9 ± 4.2{\%}) and in the percentage of β(s) globin chains in very young mice (from 44.5 ± 0.6{\%} to 40.8 ± 0.7{\%}). These results demonstrate that it is possible to decrease the concentration of β(s) chains and mRNA with the help of a hammerhead ribozyme. While the enormous amount of globin mRNA in reticulocytes is a challenge for ribozyme technology, the exquisite dependence of the delay time for formation of Hb S nuclei on the concentration of Hb S in red blood cells suggests that even a modest reduction in Hb S concentration would have therapeutic value.",
keywords = "Beta-globin, Gene therapy, Hammerhead ribozyme, Mouse model, Sickle cell anemia",
author = "Raouf Alami and Gilman, {John G.} and Feng, {Y. Q.} and Antonietta Marmorato and Ilia Rochlin and Suzuka, {Sandra M.} and Fabry, {Mary E.} and Nagel, {Ronald L.} and Bouhassira, {Eric E.}",
year = "1999",
month = "4",
doi = "10.1006/bcmd.1999.0235",
language = "English (US)",
volume = "25",
pages = "110--119",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Anti-β(s)-ribozyme reduces β(s) mRNA levels in transgenic mice

T2 - Potential application to the gene therapy of sickle cell anemia

AU - Alami, Raouf

AU - Gilman, John G.

AU - Feng, Y. Q.

AU - Marmorato, Antonietta

AU - Rochlin, Ilia

AU - Suzuka, Sandra M.

AU - Fabry, Mary E.

AU - Nagel, Ronald L.

AU - Bouhassira, Eric E.

PY - 1999/4

Y1 - 1999/4

N2 - Our current strategy for gene therapy of sickle cell anemia involves retroviral vectors capable of transducing 'designer' globin genes that code for novel anti-sickling globins (while resisting digestion by a ribozyme), coupled with the expression of a hammerhead ribozyme that can selectively cleave the human β(s) mRNA. In this report, we have tested in vivo an anti- β(s) hammerhead ribozyme embedded within a cDNA coding for the luciferase reporter gene driven by the human β-globin promoter and hyper-sensitive sites 3 and 4 of the locus control region. We have created mice transgenic for this luciferase-ribozyme construct and bred the ribozyme transgene into mice that were already transgenic for the human β(s) gene. We then measured expression of the β(s) transgene at the protein and RNA levels by HPLC and primer extension. The presence of the ribozyme was associated with a statistically significant reduction in the level of β(s) mRNA in spleen stress reticulocytes (from 60.5±4.1% to 52.9 ± 4.2%) and in the percentage of β(s) globin chains in very young mice (from 44.5 ± 0.6% to 40.8 ± 0.7%). These results demonstrate that it is possible to decrease the concentration of β(s) chains and mRNA with the help of a hammerhead ribozyme. While the enormous amount of globin mRNA in reticulocytes is a challenge for ribozyme technology, the exquisite dependence of the delay time for formation of Hb S nuclei on the concentration of Hb S in red blood cells suggests that even a modest reduction in Hb S concentration would have therapeutic value.

AB - Our current strategy for gene therapy of sickle cell anemia involves retroviral vectors capable of transducing 'designer' globin genes that code for novel anti-sickling globins (while resisting digestion by a ribozyme), coupled with the expression of a hammerhead ribozyme that can selectively cleave the human β(s) mRNA. In this report, we have tested in vivo an anti- β(s) hammerhead ribozyme embedded within a cDNA coding for the luciferase reporter gene driven by the human β-globin promoter and hyper-sensitive sites 3 and 4 of the locus control region. We have created mice transgenic for this luciferase-ribozyme construct and bred the ribozyme transgene into mice that were already transgenic for the human β(s) gene. We then measured expression of the β(s) transgene at the protein and RNA levels by HPLC and primer extension. The presence of the ribozyme was associated with a statistically significant reduction in the level of β(s) mRNA in spleen stress reticulocytes (from 60.5±4.1% to 52.9 ± 4.2%) and in the percentage of β(s) globin chains in very young mice (from 44.5 ± 0.6% to 40.8 ± 0.7%). These results demonstrate that it is possible to decrease the concentration of β(s) chains and mRNA with the help of a hammerhead ribozyme. While the enormous amount of globin mRNA in reticulocytes is a challenge for ribozyme technology, the exquisite dependence of the delay time for formation of Hb S nuclei on the concentration of Hb S in red blood cells suggests that even a modest reduction in Hb S concentration would have therapeutic value.

KW - Beta-globin

KW - Gene therapy

KW - Hammerhead ribozyme

KW - Mouse model

KW - Sickle cell anemia

UR - http://www.scopus.com/inward/record.url?scp=0033027061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033027061&partnerID=8YFLogxK

U2 - 10.1006/bcmd.1999.0235

DO - 10.1006/bcmd.1999.0235

M3 - Article

C2 - 10389593

AN - SCOPUS:0033027061

VL - 25

SP - 110

EP - 119

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 2

ER -